CDC Logo Tuberculosis Information CD-ROM   Image of people
jump over main navigation bar to content area
TB Guidelines
Surveillance Reports
Slide Sets
TB-Related MMWRs and Reports
Education/Training Materials
Ordering Information


U.S. Department of Health and Human Services


This is an archived document. The links are no longer being updated.

TB Notes 3, 2001

News Briefs

Surveillance data for the year 2000 were posted on October 2, 2001, to the DTBE Web site: . You will find it on the DTBE Home page under “What’s New.”

Several NTCA Workgroup meetings are being held this fall. On October 18 and 19 the NTCA met with CDC staff to discuss the development of a “hands-on” genotyping manual for TB controllers. The NTCA Information Technology Workgroup will be meeting with CDC staff on November 6 for what is being called a TIMS summit. Also, the NTCA Contact Investigation Workgroup will meet in Atlanta November 15-16.

Please note that a new drug called Remicade, which is labeled and approved for use in patients with rheumatoid arthritis, is associated with reactivation of latent TB infection. Because of this reaction, persons receiving Remicade should first receive a tuberculin skin test, and should not take the drug if found to have latent TB infection.


Released October 2008
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination -

Please send comments/suggestions/requests to:, or to
CDC/Division of Tuberculosis Elimination
Communications, Education, and Behavioral Studies Branch
1600 Clifton Rd., NE - Mailstop E-10, Atlanta, GA 30333